nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP1B1—ovarian cancer	0.264	0.777	CbGaD
Lansoprazole—MAPT—Paclitaxel—ovarian cancer	0.169	0.352	CbGbCtD
Lansoprazole—MAPT—Docetaxel—ovarian cancer	0.122	0.254	CbGbCtD
Lansoprazole—ABCB1—ovarian cancer	0.0758	0.223	CbGaD
Lansoprazole—CYP1B1—Paclitaxel—ovarian cancer	0.0268	0.0558	CbGbCtD
Lansoprazole—ABCG2—Topotecan—ovarian cancer	0.0257	0.0536	CbGbCtD
Lansoprazole—CYP1B1—Docetaxel—ovarian cancer	0.0194	0.0403	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—ovarian cancer	0.0144	0.0301	CbGbCtD
Lansoprazole—ABCG2—Paclitaxel—ovarian cancer	0.0127	0.0265	CbGbCtD
Lansoprazole—ABCG2—Carboplatin—ovarian cancer	0.012	0.025	CbGbCtD
Lansoprazole—ABCB1—Topotecan—ovarian cancer	0.00928	0.0193	CbGbCtD
Lansoprazole—ABCG2—Docetaxel—ovarian cancer	0.00921	0.0192	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—ovarian cancer	0.00687	0.0143	CbGbCtD
Lansoprazole—CYP2C8—Paclitaxel—ovarian cancer	0.00679	0.0141	CbGbCtD
Lansoprazole—ABCB1—Vinorelbine—ovarian cancer	0.00654	0.0136	CbGbCtD
Lansoprazole—CYP2D6—Vinorelbine—ovarian cancer	0.00616	0.0128	CbGbCtD
Lansoprazole—CYP3A4—Topotecan—ovarian cancer	0.00556	0.0116	CbGbCtD
Lansoprazole—CYP2C9—Paclitaxel—ovarian cancer	0.00473	0.00985	CbGbCtD
Lansoprazole—ABCB1—Paclitaxel—ovarian cancer	0.00459	0.00956	CbGbCtD
Lansoprazole—CYP3A4—Vinorelbine—ovarian cancer	0.00392	0.00815	CbGbCtD
Lansoprazole—ABCB1—Docetaxel—ovarian cancer	0.00332	0.00691	CbGbCtD
Lansoprazole—CYP3A4—Paclitaxel—ovarian cancer	0.00275	0.00573	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—ovarian cancer	0.00248	0.00515	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—ovarian cancer	0.00233	0.00485	CbGbCtD
Lansoprazole—CYP3A4—Docetaxel—ovarian cancer	0.00199	0.00414	CbGbCtD
Lansoprazole—CYP3A4—Doxorubicin—ovarian cancer	0.00148	0.00309	CbGbCtD
Lansoprazole—ATP4A—epithelium—ovarian cancer	0.000943	0.0648	CbGeAlD
Lansoprazole—Omeprazole—CYP1B1—ovarian cancer	0.000872	0.61	CrCbGaD
Lansoprazole—CYP4A11—vagina—ovarian cancer	0.000786	0.054	CbGeAlD
Lansoprazole—CYP2C18—uterine cervix—ovarian cancer	0.000768	0.0528	CbGeAlD
Lansoprazole—MAPT—testis—ovarian cancer	0.000761	0.0523	CbGeAlD
Lansoprazole—ATP4A—female reproductive system—ovarian cancer	0.0007	0.0481	CbGeAlD
Lansoprazole—ATP4A—testis—ovarian cancer	0.000565	0.0388	CbGeAlD
Lansoprazole—MAPT—lymph node—ovarian cancer	0.000552	0.0379	CbGeAlD
Lansoprazole—CYP2C18—vagina—ovarian cancer	0.000521	0.0358	CbGeAlD
Lansoprazole—ABCG2—myometrium—ovarian cancer	0.000356	0.0245	CbGeAlD
Lansoprazole—CYP1B1—decidua—ovarian cancer	0.000355	0.0244	CbGeAlD
Lansoprazole—CYP1B1—gonad—ovarian cancer	0.000312	0.0214	CbGeAlD
Lansoprazole—CYP1B1—uterus—ovarian cancer	0.00031	0.0213	CbGeAlD
Lansoprazole—Pantoprazole—ABCB1—ovarian cancer	0.000307	0.215	CrCbGaD
Lansoprazole—CYP1B1—female reproductive system—ovarian cancer	0.000279	0.0192	CbGeAlD
Lansoprazole—ABCG2—uterine cervix—ovarian cancer	0.000277	0.019	CbGeAlD
Lansoprazole—CYP1A1—epithelium—ovarian cancer	0.000265	0.0182	CbGeAlD
Lansoprazole—ABCG2—decidua—ovarian cancer	0.000264	0.0181	CbGeAlD
Lansoprazole—CYP1A1—uterine cervix—ovarian cancer	0.000263	0.0181	CbGeAlD
Lansoprazole—CYP2C8—endometrium—ovarian cancer	0.000258	0.0177	CbGeAlD
Lansoprazole—CYP1B1—female gonad—ovarian cancer	0.000254	0.0174	CbGeAlD
Lansoprazole—ABCG2—endometrium—ovarian cancer	0.000251	0.0172	CbGeAlD
Lansoprazole—Omeprazole—ABCB1—ovarian cancer	0.00025	0.175	CrCbGaD
Lansoprazole—ABCG2—uterus—ovarian cancer	0.000231	0.0159	CbGeAlD
Lansoprazole—CYP1B1—testis—ovarian cancer	0.000225	0.0155	CbGeAlD
Lansoprazole—CYP2C19—vagina—ovarian cancer	0.000221	0.0152	CbGeAlD
Lansoprazole—CYP1A1—uterus—ovarian cancer	0.000219	0.0151	CbGeAlD
Lansoprazole—CYP2C8—female reproductive system—ovarian cancer	0.000214	0.0147	CbGeAlD
Lansoprazole—CYP1A1—female reproductive system—ovarian cancer	0.000197	0.0135	CbGeAlD
Lansoprazole—ABCG2—bone marrow—ovarian cancer	0.000196	0.0135	CbGeAlD
Lansoprazole—CYP2C8—vagina—ovarian cancer	0.000193	0.0133	CbGeAlD
Lansoprazole—CYP2C9—female reproductive system—ovarian cancer	0.00019	0.013	CbGeAlD
Lansoprazole—ABCG2—female gonad—ovarian cancer	0.000189	0.013	CbGeAlD
Lansoprazole—ABCG2—vagina—ovarian cancer	0.000188	0.0129	CbGeAlD
Lansoprazole—CYP1A1—female gonad—ovarian cancer	0.000179	0.0123	CbGeAlD
Lansoprazole—CYP1A1—vagina—ovarian cancer	0.000178	0.0122	CbGeAlD
Lansoprazole—ABCB1—myometrium—ovarian cancer	0.000176	0.0121	CbGeAlD
Lansoprazole—CYP2C8—testis—ovarian cancer	0.000172	0.0118	CbGeAlD
Lansoprazole—ABCB1—embryo—ovarian cancer	0.000169	0.0116	CbGeAlD
Lansoprazole—ABCG2—testis—ovarian cancer	0.000168	0.0115	CbGeAlD
Lansoprazole—CYP1B1—lymph node—ovarian cancer	0.000163	0.0112	CbGeAlD
Lansoprazole—CYP3A4—female reproductive system—ovarian cancer	0.000145	0.00994	CbGeAlD
Lansoprazole—CYP2D6—female reproductive system—ovarian cancer	0.000142	0.00978	CbGeAlD
Lansoprazole—ABCB1—epithelium—ovarian cancer	0.000138	0.00947	CbGeAlD
Lansoprazole—ABCB1—uterine cervix—ovarian cancer	0.000137	0.00939	CbGeAlD
Lansoprazole—ABCB1—decidua—ovarian cancer	0.00013	0.00894	CbGeAlD
Lansoprazole—CYP2D6—female gonad—ovarian cancer	0.00013	0.0089	CbGeAlD
Lansoprazole—ABCB1—endometrium—ovarian cancer	0.000124	0.00849	CbGeAlD
Lansoprazole—ABCG2—lymph node—ovarian cancer	0.000121	0.00834	CbGeAlD
Lansoprazole—CYP1A1—lymph node—ovarian cancer	0.000115	0.00792	CbGeAlD
Lansoprazole—CYP2D6—testis—ovarian cancer	0.000115	0.00789	CbGeAlD
Lansoprazole—ABCB1—gonad—ovarian cancer	0.000115	0.00787	CbGeAlD
Lansoprazole—ABCB1—uterus—ovarian cancer	0.000114	0.00782	CbGeAlD
Lansoprazole—ABCB1—female reproductive system—ovarian cancer	0.000102	0.00703	CbGeAlD
Lansoprazole—ABCB1—bone marrow—ovarian cancer	9.67e-05	0.00664	CbGeAlD
Lansoprazole—ABCB1—female gonad—ovarian cancer	9.32e-05	0.0064	CbGeAlD
Lansoprazole—ABCB1—vagina—ovarian cancer	9.26e-05	0.00636	CbGeAlD
Lansoprazole—ABCB1—testis—ovarian cancer	8.26e-05	0.00568	CbGeAlD
Lansoprazole—ABCB1—lymph node—ovarian cancer	5.99e-05	0.00411	CbGeAlD
Lansoprazole—Constipation—Paclitaxel—ovarian cancer	4.65e-05	0.000398	CcSEcCtD
Lansoprazole—Haematuria—Epirubicin—ovarian cancer	4.65e-05	0.000397	CcSEcCtD
Lansoprazole—Confusional state—Docetaxel—ovarian cancer	4.65e-05	0.000397	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Doxorubicin—ovarian cancer	4.62e-05	0.000395	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Epirubicin—ovarian cancer	4.61e-05	0.000394	CcSEcCtD
Lansoprazole—Anaphylactic shock—Docetaxel—ovarian cancer	4.61e-05	0.000394	CcSEcCtD
Lansoprazole—Oedema—Docetaxel—ovarian cancer	4.61e-05	0.000394	CcSEcCtD
Lansoprazole—Weight increased—Doxorubicin—ovarian cancer	4.61e-05	0.000394	CcSEcCtD
Lansoprazole—Epistaxis—Epirubicin—ovarian cancer	4.6e-05	0.000393	CcSEcCtD
Lansoprazole—Infection—Docetaxel—ovarian cancer	4.58e-05	0.000392	CcSEcCtD
Lansoprazole—Sinusitis—Epirubicin—ovarian cancer	4.58e-05	0.000391	CcSEcCtD
Lansoprazole—Hyperglycaemia—Doxorubicin—ovarian cancer	4.57e-05	0.00039	CcSEcCtD
Lansoprazole—Agranulocytosis—Epirubicin—ovarian cancer	4.55e-05	0.000389	CcSEcCtD
Lansoprazole—Pneumonia—Doxorubicin—ovarian cancer	4.54e-05	0.000388	CcSEcCtD
Lansoprazole—Shock—Docetaxel—ovarian cancer	4.54e-05	0.000388	CcSEcCtD
Lansoprazole—Nervous system disorder—Docetaxel—ovarian cancer	4.52e-05	0.000387	CcSEcCtD
Lansoprazole—Thrombocytopenia—Docetaxel—ovarian cancer	4.52e-05	0.000386	CcSEcCtD
Lansoprazole—Infestation NOS—Doxorubicin—ovarian cancer	4.51e-05	0.000386	CcSEcCtD
Lansoprazole—Infestation—Doxorubicin—ovarian cancer	4.51e-05	0.000386	CcSEcCtD
Lansoprazole—Tachycardia—Docetaxel—ovarian cancer	4.5e-05	0.000385	CcSEcCtD
Lansoprazole—Feeling abnormal—Paclitaxel—ovarian cancer	4.48e-05	0.000383	CcSEcCtD
Lansoprazole—Skin disorder—Docetaxel—ovarian cancer	4.48e-05	0.000383	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	4.47e-05	0.000382	CcSEcCtD
Lansoprazole—Bradycardia—Epirubicin—ovarian cancer	4.46e-05	0.000381	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Paclitaxel—ovarian cancer	4.45e-05	0.00038	CcSEcCtD
Lansoprazole—Renal failure—Doxorubicin—ovarian cancer	4.44e-05	0.000379	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Doxorubicin—ovarian cancer	4.42e-05	0.000378	CcSEcCtD
Lansoprazole—Jaundice—Doxorubicin—ovarian cancer	4.4e-05	0.000376	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—ovarian cancer	4.4e-05	0.000376	CcSEcCtD
Lansoprazole—Anorexia—Docetaxel—ovarian cancer	4.4e-05	0.000376	CcSEcCtD
Lansoprazole—Rhinitis—Epirubicin—ovarian cancer	4.39e-05	0.000375	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—ovarian cancer	4.39e-05	0.000375	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—ovarian cancer	4.39e-05	0.000375	CcSEcCtD
Lansoprazole—Hepatitis—Epirubicin—ovarian cancer	4.38e-05	0.000374	CcSEcCtD
Lansoprazole—Hypoaesthesia—Epirubicin—ovarian cancer	4.36e-05	0.000372	CcSEcCtD
Lansoprazole—Pharyngitis—Epirubicin—ovarian cancer	4.35e-05	0.000371	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—ovarian cancer	4.33e-05	0.00037	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—ovarian cancer	4.32e-05	0.00037	CcSEcCtD
Lansoprazole—Urticaria—Paclitaxel—ovarian cancer	4.32e-05	0.000369	CcSEcCtD
Lansoprazole—Oedema peripheral—Epirubicin—ovarian cancer	4.31e-05	0.000369	CcSEcCtD
Lansoprazole—Hypotension—Docetaxel—ovarian cancer	4.31e-05	0.000368	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—ovarian cancer	4.3e-05	0.000368	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—ovarian cancer	4.3e-05	0.000368	CcSEcCtD
Lansoprazole—Abdominal pain—Paclitaxel—ovarian cancer	4.3e-05	0.000368	CcSEcCtD
Lansoprazole—Body temperature increased—Paclitaxel—ovarian cancer	4.3e-05	0.000368	CcSEcCtD
Lansoprazole—Urethral disorder—Epirubicin—ovarian cancer	4.29e-05	0.000367	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—ovarian cancer	4.27e-05	0.000365	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—ovarian cancer	4.26e-05	0.000364	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—ovarian cancer	4.23e-05	0.000362	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—ovarian cancer	4.22e-05	0.000361	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—ovarian cancer	4.21e-05	0.00036	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Docetaxel—ovarian cancer	4.2e-05	0.000359	CcSEcCtD
Lansoprazole—Insomnia—Docetaxel—ovarian cancer	4.17e-05	0.000356	CcSEcCtD
Lansoprazole—Paraesthesia—Docetaxel—ovarian cancer	4.14e-05	0.000354	CcSEcCtD
Lansoprazole—Erythema multiforme—Epirubicin—ovarian cancer	4.14e-05	0.000354	CcSEcCtD
Lansoprazole—Bradycardia—Doxorubicin—ovarian cancer	4.12e-05	0.000352	CcSEcCtD
Lansoprazole—Dyspnoea—Docetaxel—ovarian cancer	4.11e-05	0.000351	CcSEcCtD
Lansoprazole—Somnolence—Docetaxel—ovarian cancer	4.1e-05	0.00035	CcSEcCtD
Lansoprazole—Eye disorder—Epirubicin—ovarian cancer	4.09e-05	0.00035	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—ovarian cancer	4.08e-05	0.000349	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—ovarian cancer	4.06e-05	0.000347	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—ovarian cancer	4.06e-05	0.000347	CcSEcCtD
Lansoprazole—Dyspepsia—Docetaxel—ovarian cancer	4.06e-05	0.000347	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—ovarian cancer	4.05e-05	0.000346	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—ovarian cancer	4.03e-05	0.000344	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—ovarian cancer	4.02e-05	0.000344	CcSEcCtD
Lansoprazole—Decreased appetite—Docetaxel—ovarian cancer	4.01e-05	0.000343	CcSEcCtD
Lansoprazole—Hypersensitivity—Paclitaxel—ovarian cancer	4.01e-05	0.000343	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—ovarian cancer	4e-05	0.000342	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—ovarian cancer	3.99e-05	0.000341	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Docetaxel—ovarian cancer	3.98e-05	0.00034	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—ovarian cancer	3.98e-05	0.00034	CcSEcCtD
Lansoprazole—Fatigue—Docetaxel—ovarian cancer	3.98e-05	0.00034	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—ovarian cancer	3.97e-05	0.000339	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—ovarian cancer	3.97e-05	0.000339	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—ovarian cancer	3.95e-05	0.000338	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—ovarian cancer	3.95e-05	0.000337	CcSEcCtD
Lansoprazole—Pain—Docetaxel—ovarian cancer	3.94e-05	0.000337	CcSEcCtD
Lansoprazole—Constipation—Docetaxel—ovarian cancer	3.94e-05	0.000337	CcSEcCtD
Lansoprazole—Chills—Epirubicin—ovarian cancer	3.93e-05	0.000336	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—ovarian cancer	3.91e-05	0.000334	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—ovarian cancer	3.9e-05	0.000334	CcSEcCtD
Lansoprazole—Asthenia—Paclitaxel—ovarian cancer	3.9e-05	0.000334	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—ovarian cancer	3.87e-05	0.000331	CcSEcCtD
Lansoprazole—Pruritus—Paclitaxel—ovarian cancer	3.85e-05	0.000329	CcSEcCtD
Lansoprazole—Mental disorder—Epirubicin—ovarian cancer	3.84e-05	0.000328	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—ovarian cancer	3.83e-05	0.000327	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—ovarian cancer	3.81e-05	0.000326	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—ovarian cancer	3.81e-05	0.000326	CcSEcCtD
Lansoprazole—Feeling abnormal—Docetaxel—ovarian cancer	3.8e-05	0.000325	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—ovarian cancer	3.79e-05	0.000324	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—ovarian cancer	3.78e-05	0.000323	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Docetaxel—ovarian cancer	3.77e-05	0.000322	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—ovarian cancer	3.76e-05	0.000321	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—ovarian cancer	3.76e-05	0.000321	CcSEcCtD
Lansoprazole—Tension—Epirubicin—ovarian cancer	3.74e-05	0.00032	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—ovarian cancer	3.73e-05	0.000319	CcSEcCtD
Lansoprazole—Diarrhoea—Paclitaxel—ovarian cancer	3.72e-05	0.000318	CcSEcCtD
Lansoprazole—Nervousness—Epirubicin—ovarian cancer	3.7e-05	0.000316	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—ovarian cancer	3.69e-05	0.000315	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—ovarian cancer	3.68e-05	0.000314	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—ovarian cancer	3.66e-05	0.000313	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—ovarian cancer	3.66e-05	0.000313	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—ovarian cancer	3.65e-05	0.000312	CcSEcCtD
Lansoprazole—Body temperature increased—Docetaxel—ovarian cancer	3.65e-05	0.000312	CcSEcCtD
Lansoprazole—Abdominal pain—Docetaxel—ovarian cancer	3.65e-05	0.000312	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—ovarian cancer	3.64e-05	0.000311	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—ovarian cancer	3.62e-05	0.000309	CcSEcCtD
Lansoprazole—Dizziness—Paclitaxel—ovarian cancer	3.6e-05	0.000307	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—ovarian cancer	3.59e-05	0.000307	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—ovarian cancer	3.58e-05	0.000306	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—ovarian cancer	3.55e-05	0.000303	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—ovarian cancer	3.54e-05	0.000302	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—ovarian cancer	3.53e-05	0.000301	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—ovarian cancer	3.53e-05	0.000301	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—ovarian cancer	3.52e-05	0.000301	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—ovarian cancer	3.5e-05	0.000299	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—ovarian cancer	3.48e-05	0.000297	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—ovarian cancer	3.46e-05	0.000296	CcSEcCtD
Lansoprazole—Vomiting—Paclitaxel—ovarian cancer	3.46e-05	0.000296	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—ovarian cancer	3.45e-05	0.000295	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—ovarian cancer	3.44e-05	0.000294	CcSEcCtD
Lansoprazole—Rash—Paclitaxel—ovarian cancer	3.43e-05	0.000293	CcSEcCtD
Lansoprazole—Dermatitis—Paclitaxel—ovarian cancer	3.43e-05	0.000293	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—ovarian cancer	3.43e-05	0.000293	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—ovarian cancer	3.42e-05	0.000293	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—ovarian cancer	3.42e-05	0.000292	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—ovarian cancer	3.41e-05	0.000292	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—ovarian cancer	3.41e-05	0.000292	CcSEcCtD
Lansoprazole—Headache—Paclitaxel—ovarian cancer	3.41e-05	0.000291	CcSEcCtD
Lansoprazole—Hypersensitivity—Docetaxel—ovarian cancer	3.4e-05	0.00029	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—ovarian cancer	3.39e-05	0.00029	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—ovarian cancer	3.37e-05	0.000288	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—ovarian cancer	3.35e-05	0.000286	CcSEcCtD
Lansoprazole—Cough—Epirubicin—ovarian cancer	3.33e-05	0.000284	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—ovarian cancer	3.32e-05	0.000284	CcSEcCtD
Lansoprazole—Asthenia—Docetaxel—ovarian cancer	3.31e-05	0.000283	CcSEcCtD
Lansoprazole—Convulsion—Epirubicin—ovarian cancer	3.3e-05	0.000282	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—ovarian cancer	3.29e-05	0.000281	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—ovarian cancer	3.27e-05	0.00028	CcSEcCtD
Lansoprazole—Pruritus—Docetaxel—ovarian cancer	3.26e-05	0.000279	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—ovarian cancer	3.26e-05	0.000279	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—ovarian cancer	3.24e-05	0.000277	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—ovarian cancer	3.24e-05	0.000277	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—ovarian cancer	3.24e-05	0.000277	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—ovarian cancer	3.24e-05	0.000277	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—ovarian cancer	3.23e-05	0.000276	CcSEcCtD
Lansoprazole—Nausea—Paclitaxel—ovarian cancer	3.23e-05	0.000276	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	3.22e-05	0.000275	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—ovarian cancer	3.21e-05	0.000274	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—ovarian cancer	3.18e-05	0.000272	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—ovarian cancer	3.17e-05	0.000271	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—ovarian cancer	3.17e-05	0.000271	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—ovarian cancer	3.16e-05	0.00027	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—ovarian cancer	3.16e-05	0.00027	CcSEcCtD
Lansoprazole—Diarrhoea—Docetaxel—ovarian cancer	3.16e-05	0.00027	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—ovarian cancer	3.14e-05	0.000268	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—ovarian cancer	3.12e-05	0.000266	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—ovarian cancer	3.11e-05	0.000266	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—ovarian cancer	3.11e-05	0.000266	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—ovarian cancer	3.1e-05	0.000265	CcSEcCtD
Lansoprazole—Infection—Epirubicin—ovarian cancer	3.09e-05	0.000264	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—ovarian cancer	3.08e-05	0.000263	CcSEcCtD
Lansoprazole—Shock—Epirubicin—ovarian cancer	3.06e-05	0.000262	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—ovarian cancer	3.06e-05	0.000261	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—ovarian cancer	3.05e-05	0.000261	CcSEcCtD
Lansoprazole—Dizziness—Docetaxel—ovarian cancer	3.05e-05	0.000261	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—ovarian cancer	3.05e-05	0.00026	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—ovarian cancer	3.04e-05	0.00026	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—ovarian cancer	3.04e-05	0.000259	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—ovarian cancer	3.02e-05	0.000258	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—ovarian cancer	3.01e-05	0.000257	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—ovarian cancer	3e-05	0.000257	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—ovarian cancer	3e-05	0.000257	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—ovarian cancer	3e-05	0.000257	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—ovarian cancer	2.99e-05	0.000256	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	2.98e-05	0.000255	CcSEcCtD
Lansoprazole—Discomfort—Doxorubicin—ovarian cancer	2.97e-05	0.000254	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—ovarian cancer	2.97e-05	0.000253	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—ovarian cancer	2.94e-05	0.000251	CcSEcCtD
Lansoprazole—Vomiting—Docetaxel—ovarian cancer	2.93e-05	0.000251	CcSEcCtD
Lansoprazole—Rash—Docetaxel—ovarian cancer	2.91e-05	0.000249	CcSEcCtD
Lansoprazole—Hypotension—Epirubicin—ovarian cancer	2.91e-05	0.000248	CcSEcCtD
Lansoprazole—Dermatitis—Docetaxel—ovarian cancer	2.91e-05	0.000248	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—ovarian cancer	2.9e-05	0.000248	CcSEcCtD
Lansoprazole—Headache—Docetaxel—ovarian cancer	2.89e-05	0.000247	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—ovarian cancer	2.88e-05	0.000246	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—ovarian cancer	2.88e-05	0.000246	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—ovarian cancer	2.86e-05	0.000244	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—ovarian cancer	2.83e-05	0.000242	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—ovarian cancer	2.83e-05	0.000242	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—ovarian cancer	2.82e-05	0.000241	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—ovarian cancer	2.82e-05	0.000241	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—ovarian cancer	2.81e-05	0.00024	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—ovarian cancer	2.81e-05	0.00024	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—ovarian cancer	2.8e-05	0.000239	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—ovarian cancer	2.79e-05	0.000239	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—ovarian cancer	2.78e-05	0.000238	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—ovarian cancer	2.77e-05	0.000237	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—ovarian cancer	2.77e-05	0.000236	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—ovarian cancer	2.74e-05	0.000234	CcSEcCtD
Lansoprazole—Nausea—Docetaxel—ovarian cancer	2.74e-05	0.000234	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—ovarian cancer	2.74e-05	0.000234	CcSEcCtD
Lansoprazole—Decreased appetite—Epirubicin—ovarian cancer	2.7e-05	0.000231	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—ovarian cancer	2.69e-05	0.00023	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—ovarian cancer	2.69e-05	0.00023	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—ovarian cancer	2.68e-05	0.000229	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—ovarian cancer	2.66e-05	0.000227	CcSEcCtD
Lansoprazole—Pain—Epirubicin—ovarian cancer	2.66e-05	0.000227	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	2.62e-05	0.000224	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—ovarian cancer	2.6e-05	0.000222	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—ovarian cancer	2.58e-05	0.000221	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—ovarian cancer	2.57e-05	0.000219	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—ovarian cancer	2.56e-05	0.000219	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—ovarian cancer	2.56e-05	0.000219	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—ovarian cancer	2.54e-05	0.000217	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—ovarian cancer	2.53e-05	0.000217	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—ovarian cancer	2.5e-05	0.000214	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—ovarian cancer	2.48e-05	0.000212	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—ovarian cancer	2.48e-05	0.000212	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—ovarian cancer	2.47e-05	0.000211	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—ovarian cancer	2.46e-05	0.00021	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—ovarian cancer	2.46e-05	0.00021	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—ovarian cancer	2.46e-05	0.00021	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—ovarian cancer	2.46e-05	0.00021	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—ovarian cancer	2.37e-05	0.000203	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—ovarian cancer	2.35e-05	0.000201	CcSEcCtD
Lansoprazole—Hypersensitivity—Epirubicin—ovarian cancer	2.29e-05	0.000196	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—ovarian cancer	2.29e-05	0.000195	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—ovarian cancer	2.28e-05	0.000194	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—ovarian cancer	2.28e-05	0.000194	CcSEcCtD
Lansoprazole—Asthenia—Epirubicin—ovarian cancer	2.23e-05	0.000191	CcSEcCtD
Lansoprazole—Pruritus—Epirubicin—ovarian cancer	2.2e-05	0.000188	CcSEcCtD
Lansoprazole—Diarrhoea—Epirubicin—ovarian cancer	2.13e-05	0.000182	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—ovarian cancer	2.12e-05	0.000181	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—ovarian cancer	2.07e-05	0.000176	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—ovarian cancer	2.06e-05	0.000176	CcSEcCtD
Lansoprazole—Pruritus—Doxorubicin—ovarian cancer	2.04e-05	0.000174	CcSEcCtD
Lansoprazole—Vomiting—Epirubicin—ovarian cancer	1.98e-05	0.000169	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—ovarian cancer	1.97e-05	0.000168	CcSEcCtD
Lansoprazole—Rash—Epirubicin—ovarian cancer	1.96e-05	0.000168	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—ovarian cancer	1.96e-05	0.000167	CcSEcCtD
Lansoprazole—Headache—Epirubicin—ovarian cancer	1.95e-05	0.000167	CcSEcCtD
Lansoprazole—Dizziness—Doxorubicin—ovarian cancer	1.9e-05	0.000163	CcSEcCtD
Lansoprazole—Nausea—Epirubicin—ovarian cancer	1.85e-05	0.000158	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—ovarian cancer	1.83e-05	0.000156	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—ovarian cancer	1.81e-05	0.000155	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—ovarian cancer	1.81e-05	0.000155	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—ovarian cancer	1.8e-05	0.000154	CcSEcCtD
Lansoprazole—Nausea—Doxorubicin—ovarian cancer	1.71e-05	0.000146	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—CYTB—ovarian cancer	1.22e-05	0.000262	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ABCB1—ovarian cancer	1.2e-05	0.000258	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.19e-05	0.000256	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—TYMS—ovarian cancer	1.18e-05	0.000254	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.17e-05	0.000251	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—BRIP1—ovarian cancer	1.16e-05	0.00025	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPP1CC—ovarian cancer	1.16e-05	0.00025	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—YAP1—ovarian cancer	1.15e-05	0.000248	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	1.14e-05	0.000247	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PPP2R1A—ovarian cancer	1.13e-05	0.000243	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.12e-05	0.00024	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.1e-05	0.000237	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYTB—ovarian cancer	1.09e-05	0.000234	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.07e-05	0.000229	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—BRIP1—ovarian cancer	1.06e-05	0.000229	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPP1CC—ovarian cancer	1.06e-05	0.000229	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.06e-05	0.000229	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.06e-05	0.000229	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYTB—ovarian cancer	1.06e-05	0.000228	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	1.06e-05	0.000228	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ABCB1—ovarian cancer	1.05e-05	0.000226	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	1.04e-05	0.000224	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—FASN—ovarian cancer	1.03e-05	0.000222	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—TYMS—ovarian cancer	1.03e-05	0.000222	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.03e-05	0.000221	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NME2—ovarian cancer	1.01e-05	0.000218	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SLC5A5—ovarian cancer	1.01e-05	0.000218	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	1.01e-05	0.000218	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	1e-05	0.000216	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYTB—ovarian cancer	1e-05	0.000215	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYTB—ovarian cancer	9.91e-06	0.000213	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SLC2A1—ovarian cancer	9.8e-06	0.000211	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	9.76e-06	0.00021	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	9.69e-06	0.000209	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.59e-06	0.000207	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPP1CC—ovarian cancer	9.5e-06	0.000205	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—BRIP1—ovarian cancer	9.5e-06	0.000205	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CAV1—ovarian cancer	9.5e-06	0.000204	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—FASN—ovarian cancer	9.38e-06	0.000202	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—BRIP1—ovarian cancer	9.28e-06	0.0002	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPP1CC—ovarian cancer	9.28e-06	0.0002	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SLC5A5—ovarian cancer	9.23e-06	0.000199	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	9.09e-06	0.000196	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.07e-06	0.000195	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SLC2A1—ovarian cancer	8.91e-06	0.000192	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	8.82e-06	0.00019	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPP1CC—ovarian cancer	8.74e-06	0.000188	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—BRIP1—ovarian cancer	8.74e-06	0.000188	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPP1CC—ovarian cancer	8.67e-06	0.000187	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—BRIP1—ovarian cancer	8.67e-06	0.000187	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CG—ovarian cancer	8.65e-06	0.000186	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP1B1—ovarian cancer	8.54e-06	0.000184	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYTB—ovarian cancer	8.47e-06	0.000182	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	8.46e-06	0.000182	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	8.34e-06	0.00018	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPP2R1A—ovarian cancer	8.33e-06	0.000179	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CAV1—ovarian cancer	8.3e-06	0.000179	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.29e-06	0.000178	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	8.28e-06	0.000178	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	8.11e-06	0.000175	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	7.94e-06	0.000171	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	7.94e-06	0.000171	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—YAP1—ovarian cancer	7.79e-06	0.000168	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.76e-06	0.000167	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ABCB1—ovarian cancer	7.73e-06	0.000167	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.71e-06	0.000166	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CD—ovarian cancer	7.61e-06	0.000164	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—TYMS—ovarian cancer	7.6e-06	0.000164	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPP2R1A—ovarian cancer	7.58e-06	0.000163	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CG—ovarian cancer	7.56e-06	0.000163	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	7.5e-06	0.000161	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPP1CC—ovarian cancer	7.41e-06	0.000159	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—BRIP1—ovarian cancer	7.41e-06	0.000159	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—YAP1—ovarian cancer	7.14e-06	0.000154	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.07e-06	0.000152	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ABCB1—ovarian cancer	7.04e-06	0.000151	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.93e-06	0.000149	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—TYMS—ovarian cancer	6.91e-06	0.000149	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.89e-06	0.000148	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.78e-06	0.000146	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.66e-06	0.000143	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CD—ovarian cancer	6.65e-06	0.000143	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CB—ovarian cancer	6.63e-06	0.000143	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYTB—ovarian cancer	6.54e-06	0.000141	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—YAP1—ovarian cancer	6.37e-06	0.000137	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—FASN—ovarian cancer	6.35e-06	0.000137	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.31e-06	0.000136	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.31e-06	0.000136	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SLC5A5—ovarian cancer	6.25e-06	0.000134	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—YAP1—ovarian cancer	6.22e-06	0.000134	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.21e-06	0.000134	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CAV1—ovarian cancer	6.12e-06	0.000132	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SLC2A1—ovarian cancer	6.03e-06	0.00013	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.91e-06	0.000127	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—YAP1—ovarian cancer	5.86e-06	0.000126	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.85e-06	0.000126	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—FASN—ovarian cancer	5.82e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—YAP1—ovarian cancer	5.81e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CB—ovarian cancer	5.79e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP1B1—ovarian cancer	5.78e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.75e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTEN—ovarian cancer	5.73e-06	0.000123	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SLC5A5—ovarian cancer	5.73e-06	0.000123	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPP1CC—ovarian cancer	5.72e-06	0.000123	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—BRIP1—ovarian cancer	5.72e-06	0.000123	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.63e-06	0.000121	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CG—ovarian cancer	5.57e-06	0.00012	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CAV1—ovarian cancer	5.57e-06	0.00012	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.55e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SLC2A1—ovarian cancer	5.53e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.42e-06	0.000117	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.4e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP1B1—ovarian cancer	5.3e-06	0.000114	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—FASN—ovarian cancer	5.2e-06	0.000112	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	5.13e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SLC5A5—ovarian cancer	5.11e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.1e-06	0.00011	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CG—ovarian cancer	5.07e-06	0.000109	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—FASN—ovarian cancer	5.07e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.06e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTEN—ovarian cancer	5.01e-06	0.000108	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC5A5—ovarian cancer	4.99e-06	0.000107	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—YAP1—ovarian cancer	4.97e-06	0.000107	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SLC2A1—ovarian cancer	4.94e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.92e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CD—ovarian cancer	4.9e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.83e-06	0.000104	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC2A1—ovarian cancer	4.82e-06	0.000104	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—FASN—ovarian cancer	4.78e-06	0.000103	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ABCB1—ovarian cancer	4.76e-06	0.000103	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—FASN—ovarian cancer	4.74e-06	0.000102	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP1B1—ovarian cancer	4.73e-06	0.000102	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	4.7e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC5A5—ovarian cancer	4.7e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.68e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—TYMS—ovarian cancer	4.68e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC5A5—ovarian cancer	4.66e-06	0.0001	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP1B1—ovarian cancer	4.62e-06	9.95e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC2A1—ovarian cancer	4.54e-06	9.78e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC2A1—ovarian cancer	4.5e-06	9.69e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CD—ovarian cancer	4.46e-06	9.6e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.41e-06	9.49e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ABCB1—ovarian cancer	4.37e-06	9.4e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP1B1—ovarian cancer	4.35e-06	9.37e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.32e-06	9.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP1B1—ovarian cancer	4.32e-06	9.29e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TYMS—ovarian cancer	4.29e-06	9.23e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CB—ovarian cancer	4.27e-06	9.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	4.2e-06	9.04e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.18e-06	8.99e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPP2R1A—ovarian cancer	4.1e-06	8.82e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—FASN—ovarian cancer	4.05e-06	8.72e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—ovarian cancer	4.04e-06	8.7e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC5A5—ovarian cancer	3.98e-06	8.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ABCB1—ovarian cancer	3.9e-06	8.39e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CB—ovarian cancer	3.89e-06	8.37e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	3.86e-06	8.31e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC2A1—ovarian cancer	3.85e-06	8.28e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—YAP1—ovarian cancer	3.83e-06	8.25e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TYMS—ovarian cancer	3.83e-06	8.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	3.83e-06	8.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.81e-06	8.2e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CAV1—ovarian cancer	3.77e-06	8.12e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.77e-06	8.11e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TYMS—ovarian cancer	3.74e-06	8.04e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTEN—ovarian cancer	3.69e-06	7.95e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP1B1—ovarian cancer	3.69e-06	7.94e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.6e-06	7.75e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ABCB1—ovarian cancer	3.58e-06	7.72e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ABCB1—ovarian cancer	3.55e-06	7.65e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—ovarian cancer	3.53e-06	7.61e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TYMS—ovarian cancer	3.52e-06	7.58e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TYMS—ovarian cancer	3.49e-06	7.51e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CAV1—ovarian cancer	3.46e-06	7.44e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CG—ovarian cancer	3.43e-06	7.39e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTEN—ovarian cancer	3.36e-06	7.23e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.3e-06	7.11e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—ovarian cancer	3.3e-06	7.11e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	3.27e-06	7.04e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.25e-06	7.01e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CG—ovarian cancer	3.15e-06	6.78e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—FASN—ovarian cancer	3.12e-06	6.73e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CAV1—ovarian cancer	3.08e-06	6.64e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.07e-06	6.62e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.04e-06	6.54e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CD—ovarian cancer	3.02e-06	6.5e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CAV1—ovarian cancer	3.01e-06	6.48e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TYMS—ovarian cancer	2.98e-06	6.42e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.97e-06	6.39e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.95e-06	6.34e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—ovarian cancer	2.89e-06	6.21e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.85e-06	6.13e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CAV1—ovarian cancer	2.84e-06	6.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CAV1—ovarian cancer	2.81e-06	6.06e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.81e-06	6.05e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CD—ovarian cancer	2.77e-06	5.96e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.74e-06	5.9e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.69e-06	5.78e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CB—ovarian cancer	2.63e-06	5.66e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—ovarian cancer	2.6e-06	5.61e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.58e-06	5.56e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.56e-06	5.52e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.52e-06	5.43e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.47e-06	5.32e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CB—ovarian cancer	2.41e-06	5.19e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.41e-06	5.19e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CAV1—ovarian cancer	2.4e-06	5.17e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—ovarian cancer	2.37e-06	5.1e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.34e-06	5.05e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TYMS—ovarian cancer	2.3e-06	4.96e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.3e-06	4.94e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTEN—ovarian cancer	2.27e-06	4.89e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.27e-06	4.89e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.25e-06	4.85e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.19e-06	4.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.15e-06	4.63e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—ovarian cancer	2.13e-06	4.58e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.1e-06	4.52e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTEN—ovarian cancer	2.08e-06	4.49e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.98e-06	4.26e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.96e-06	4.23e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—ovarian cancer	1.94e-06	4.17e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.92e-06	4.14e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTEN—ovarian cancer	1.86e-06	4.01e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CAV1—ovarian cancer	1.85e-06	3.99e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTEN—ovarian cancer	1.82e-06	3.91e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTEN—ovarian cancer	1.71e-06	3.68e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTEN—ovarian cancer	1.7e-06	3.65e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.69e-06	3.64e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.68e-06	3.61e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—ovarian cancer	1.6e-06	3.45e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.49e-06	3.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.47e-06	3.17e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTEN—ovarian cancer	1.45e-06	3.12e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.31e-06	2.83e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—ovarian cancer	1.31e-06	2.82e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.29e-06	2.79e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.28e-06	2.76e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.21e-06	2.6e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—ovarian cancer	1.2e-06	2.59e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.2e-06	2.58e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTEN—ovarian cancer	1.12e-06	2.41e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—ovarian cancer	1.07e-06	2.31e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—ovarian cancer	1.05e-06	2.25e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.02e-06	2.2e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—ovarian cancer	9.86e-07	2.12e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—ovarian cancer	9.78e-07	2.1e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—ovarian cancer	8.35e-07	1.8e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—ovarian cancer	7.89e-07	1.7e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—ovarian cancer	6.45e-07	1.39e-05	CbGpPWpGaD
